

R&D Pipeline

Only high-priority projects in the clinical stage or soon to be in the clinical stage are listed in the table.



Code Generic name (Product name)	Potential Indication	Preclinical	Clinical Trial	Application	Approval	Mechanism
JR-141 pabinafusp alfa (IZCARGO® for I.V. infusion 10mg)	MPS type II (Hunter)		Japan and UAE Global Ph3			BBB-penetrating iduronate-2-sulfatase (rDNA origin)
JR-142 redalsomatropin alfa	Pediatric growth hormone deficiency		Japan Ph3			Long-acting human growth hormone (rDNA origin)
JR-171 lepunafusp alfa	MPS type I (Hurler etc.)		Global Ph1/2			BBB-penetrating α-L-iduronidase (rDNA origin)
JR-441	MPS type III A (Sanfilippo A)		Germany Ph1/2 Japan Ph1			BBB-penetrating heparan N-sulfatase (rDNA origin)

R&D Pipeline

Only high-priority projects in the clinical stage or soon to be in the clinical stage are listed in the table.

Code Generic name (Product name)	Potential Indication	Preclinical	Clinical Trial	Application	Approval	Mechanism
JR-446	MPS type III B (Sanfilippo B)	Japan Ph1/2				BBB-penetrating α -N-acetylgluco- saminidase (rDNA origin) Partnering with MEDIPAL HOLDINGS
JR-471	Fucosidosis					BBB-penetrating α -L-fucosidase (rDNA origin) Partnering with MEDIPAL HOLDINGS
JR-479	GM2 gangliosidosis					BBB-penetrating β -hexosaminidase A (rDNA origin) Partnering with MEDIPAL HOLDINGS
Givinostat	Duchenne muscular dystrophy					Partnering with Italfamaco S.p.A. Approved in the US, the EU and other countries